ASCVD Risk Calculator

The Pooled Cohort Equations estimate 10-year risk of a first hard ASCVD event — nonfatal myocardial infarction, coronary death, or stroke — from nine inputs: age, sex, race, total and HDL cholesterol, systolic blood pressure, treatment status for hypertension, diabetes status, and current smoking. Unlike a simple point-based score, the equations are true Cox proportional-hazards models: each risk factor is log-transformed, multiplied by a sex- and race-specific coefficient, combined with interaction terms (age×cholesterol, age×smoking) that capture how risk factors compound differently as people age, and then applied to a baseline survival function unique to each demographic group. The resulting percentage feeds directly into a shared decision-making threshold structure: below 5% is low risk (lifestyle counseling only), 5-7.5% is borderline (consider risk-enhancing factors like family history or elevated Lp(a)), 7.5-20% is intermediate (moderate-intensity statin generally recommended), and 20% or higher is high risk (high-intensity statin recommended). The equations were derived and validated only in white and Black adults aged 40-79 without pre-existing ASCVD; the 2018 cholesterol guidelines explicitly flag that risk may be over- or under-estimated in other race/ethnicity groups, South Asian populations, and those with strong family history, which is why the guidelines introduce 'risk-enhancing factors' as an adjustment layer on top of the raw calculated percentage.

The Pooled Cohort Equations were developed by the ACC/AHA Risk Assessment Work Group and published alongside the landmark 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk, replacing the older Framingham Risk Score that had been the U.S. standard since the 1990s. Framingham was built almost entirely from a New England cohort with limited racial diversity and was known to systematically overestimate risk in some populations and underestimate it in others; the Pooled Cohort Equations addressed this by combining data from multiple large, more demographically diverse NHLBI-sponsored cohort studies, including ARIC, CHS, Framingham, and CARDIA. The 2013 release drew immediate methodological controversy — an analysis published in The Lancet the same year argued the equations overestimated risk by roughly 75-150% when tested against contemporary external cohorts, sparking a debate over recalibration that continued for years. The ACC and AHA subsequently built the free online ASCVD Risk Estimator Plus tool and refined guidance in the 2018 and 2019 cholesterol and primary-prevention guidelines, adding the 'risk-enhancing factors' concept and coronary artery calcium scoring as an optional tiebreaker for patients in the borderline-to-intermediate range where the raw calculated percentage alone is considered insufficient for a firm statin decision.